Maruti, Aurobindo Pharma, JSW in focus after developments

Maruti Suzuki India Ltd will increase vehicle prices by up to Rs 30,000 from August 2026 due to sustained rise in input costs.

Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics Pvt Ltd received regulatory approval from Brazil's ANVISA for its biosimilars manufacturing facility in Hyderabad.

JSW Infrastructure Ltd reported a healthy quarterly performance for quarter ended June 30, 2026, with revenue up 18% YoY to Rs 1,445 crore and profit after tax of Rs 358 crore.